This implantable medical device can be used to create an arteriovenous fistula (AVF) percutaneously, in a clinic based procedure. The AVF improves clinical outcomes for patients on hemodialysis.
Most end stage renal disease patients are treated with hemodialysis (HD). It is well established that a variety of clinic measures are improved when AVF is used over other dialysis access modalities, including decreased rates of hospitalization, infection and death. Despite clear benefits, only one out of five HD patients initiate dialysis with an AVF.
Creating dialysis access is a surgical procedure, presenting social and systems barriers to treatment. This implantable device eliminates the need for surgery, addressing some of the barriers to timely AVF creation. It can be used to create an AVF as a minimally invasive procedure in an office based procedure.
This novel invention provides the following advantages:
· Minimally invasive
· Can be performed as an office based procedure
· Cost saving for health care payers
· Does not require an x-ray for device positioning
· Better safety profile and less pain
· Negates the need for anesthesia
· Limits number of catheter days for patients on HD
· Potential for gains in life expectancy for patients on HD
Vascular Surgeons at the University of California, San Francisco have created a novel medical device that can create an AVF in patients on HD. The device consists of two parts: a crossing device and connecting device. After the surgeon has accessed the vein using standard techniques, the crossing device can be positioned with ultrasound guidance. Once the crossing device has accessed the AV fistula site, the connecting device can formalize the AV anastomosis.
Dialysis access for hemodialysis patients
To develop and commercialize this medical device as an effective method of producing a percutaneous AVF in patients with HD
Dialysis, Arteriovenous Fistula, Percutaneous Arteriovenous Fistula, Implantable Medical Device, Hemodialysis, Anastomosis